Back to News
Market Impact: 0.2
CDT Equity Partners With QIMA Life Sciences On Autoimmune Skin Research, Shares Fall In Pre-market
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
CDT Equity entered a partnership with French contract research organization QIMA Life Sciences to evaluate several of its assets for autoimmune skin diseases. The collaboration expands development exploration for CDT's biotech pipeline, though no financial terms, clinical data, or commercialization timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CDT0.45
More News
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Oracle files to sell $20 billion in new stock, bonds to finance AI buildout